ImmunityBio, Inc.
Case Overview
61 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 05/26/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: ImmunityBio, Inc. |
| Court: | Court: Central District of California |
| Case Number: | Case Number: 2:26cv03261 |
| Class Period: | Class Period: 01/19/2026 - 03/24/2026 |
| Ticker: | Ticker: IBRX |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”).
The lawsuit alleges that (1) Defendant Patrick Soon-Shiong, the Company’s Executive Chairman of the Board, materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist immunotherapy that combats cancer, in public statements.
On March 24, 2026, before markets opened, the United States Food and Drug Administration (“FDA”) issued a warning letter to ImmunityBio. The FDA stated in the warning letter that a TV ad and podcast, which can be accessed through ImmunityBio’s website, has been determined to be “false or misleading.” The FDA also stated that “Untitled Letters dated September 9, 2025, and January 7, 2026” were sent to “Altor BioScience, LLC (an indirect wholly-owned subsidiary of ImmunityBio, Inc.) [which] addressed presentations of Anktiva that were, in certain respects, similar to presentations in the TV ad and podcast addressed in this [warning] letter.” “[D]espite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner. On this news, the price of ImmunityBio shares declined by $1.99 per share, or approximately 21.2%, from $9.40 per share on March 23, 2026 to close at $7.41 on March 24, 2026.
The lawsuit alleges that (1) Defendant Patrick Soon-Shiong, the Company’s Executive Chairman of the Board, materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist immunotherapy that combats cancer, in public statements.
On March 24, 2026, before markets opened, the United States Food and Drug Administration (“FDA”) issued a warning letter to ImmunityBio. The FDA stated in the warning letter that a TV ad and podcast, which can be accessed through ImmunityBio’s website, has been determined to be “false or misleading.” The FDA also stated that “Untitled Letters dated September 9, 2025, and January 7, 2026” were sent to “Altor BioScience, LLC (an indirect wholly-owned subsidiary of ImmunityBio, Inc.) [which] addressed presentations of Anktiva that were, in certain respects, similar to presentations in the TV ad and podcast addressed in this [warning] letter.” “[D]espite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner. On this news, the price of ImmunityBio shares declined by $1.99 per share, or approximately 21.2%, from $9.40 per share on March 23, 2026 to close at $7.41 on March 24, 2026.